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Volume 52, Number 6 Abstracts 1735cefepime) group, 13% in the vancomycin cephalosporin group; and 6% in
the daptomycin  cefepime group (P  .01). The frequency of MRSA SSI
was similar (P .1) in patients receiving daptomycin (1.3%) compared to the
other prophylactic antibiotic regimens (4.8%). Overall, 41 (73%) of 56
patients with SSI required surgical therapy to achieve wound healing with
mean LOS increase of 12 days in SSI group. Outcomes at 30 days included
1.3% (4 patients) mortality and one prosthetic graft excised for infection.
Diabetes was associated with increased SSI (P  .04) while age, gender,
CAD, BMI, or renal insufficiency were not predictive of SSI.
Conclusions. This audit demonstrated one in seven patients devel-
ops SSI after arterial intervention involving the femoral artery. SSI risk
was higher in diabetics, after arterial bypass, with required therapeutic
antibiotics, and when nasal MRSA colonization was present. The most
common bacterial isolate was MRSA. The addition of a single-dose of
daptomycin (bactericidal to gram  organism including MRSA) to a
cephalosporin prophylaxis regimen significantly reduced SSI. Given the
trend to mandated hospital reporting of wound infection rates to con-
sumers, these SSI statistics are relevant and indicate an urgent need to
develop wound care strategies to augment primary healing and the
prevention of biofilm-mediated infection.
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Introduction: Although the algorithm for symptomatic and severe
carotid disease is less controversial, questions remain as to the optimal
approach toward asymptomatic moderate carotid artery stenosis. The aim
of this study is to evaluate the 10-year outcome of patients presenting
with asymptomatic moderate carotid artery stenosis and to determine
which factors correlate with progression of disease to stroke or revascu-
larization.
Methods: A retrospective review of all new patients presenting with
asymptomatic moderate carotid artery stenosis from July 1998 to December
2001 was undertaken. Variables were recorded for all patient encounters
occurring through June 2010. A novel endpoint for a stroke or revascular-
ization event was defined:
● SORE - occurrence of ipsilateral cerebrovascular event or carotid revascu-
larization
Statin therapy and angiotensin blockade (STAB) were categorized as fol-
lows:
● STAB0 - Medical treatment with neither statin therapy nor angiotensin
blockade
● STAB1 - Medical treatment with only one of these therapies
● STAB2 - Medical treatment employing both therapies
To evaluate relative cost effectiveness of STAB therapy, an amortized model
based on our previously described cost efficacy model was used to analyze
the cost of each year without SORE.
Results: Over a 42-month period, 468 carotids in 366 patients were
evaluated for asymptomatic moderate carotid artery stenosis. The average
age of the entire cohort was 68.7 years, with a predominance of hyperten-
sion, coronary artery disease, hyperlipidemia, and smoking history. The
contralateral carotid was noted to have a greater than 50% stenosis in 68.0%
of patients. Antiplatelet therapy was employed in the treatment of 84.5% of
patients, compared to statin therapy in 63.5% and angiotensin blockade in
48.3% of patients. Over a mean follow-up of 6.6 years, SORE occurred in
150 (32.1%) carotid arteries. Cases were then stratified by occurrence of
SORE. Cases without SORE were noted to have a higher rate of bilateral
stenosis greater than 50%. Antiplatelet, statin, and angiotensin blockade
were found in significantly lower rates in cases progressing to SORE.
Multivariate analysis revealed only hyperlipidemia was predictive of SORE
(HR 1.524, CI 1.039-2.236, P  .03). Medical therapy with either a statin
or angiotensin blockade (STAB1) was protective against SORE (HR 0.505,
CI 0.350-0.730, P .01), and the additive effects of both statin therapy and
angiotensin pathway blockage (STAB2) were even more pronounced (HR
0.147, CI 0.089-0.244, P  .01). Bilateral stenosis greater than 50%
continued to be protective (HR 0.420, CI 0.302-0.584, P  .01) against
SORE. At 10 years, SORE-free survival was achieved in STAB2 in
82.7  4.6%. In STAB1, 56.3  5.0% had no SORE. The STAB0 cohort
had 29.3  5.4%without SORE (P .01). The cost model revealed the cost
per SORE-free year in the STAB2 cohort to be $1695.40  $275.60, less
than 50% that of either STAB1 ($3916.80  605.44) or STAB0
($4126.40  427.23) therapy (P  .01).Conclusion: These data are the first to demonstrate the clinical and
financial advantage of using both statin therapy and angiotensin pathway
blockage in patients with asymptomatic moderate carotid artery stenosis.
Avoidance of stroke and progression to surgery in these patients, with
concurrent cost savings, implies that this strategy should be standard of care
in this at-risk population.
Trends, Charges, and Outcomes in Endovascular Therapy for Periph-
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Background: We sought to define the current trends in the use of
endovascular procedures and the impact on the associated costs and
outcomes in Florida. These data can then be used as a baseline assessment
for the development of a statewide cooperative quality improvement
program.
Methods: The Agency for Healthcare Administration (AHCA) data-
base, which contains 100% of discharges from Florida hospitals, was queried
for peripheral arterial disease (PAD) from 2000 to 2008. Discharges from
ambulatory centers were also available from 2004 to 2008 allowing more
comprehensive analysis of endovascular procedures. Angioplasty, atherec-
tomy, and peripheral stents were identified either by respective CPT codes
for ambulatory procedures, or ICD-9 procedure codes for hospital-based
procedures, comprising the endovascular group. The open bypass group was
identified using ICD-9 codes for hospital data. Major amputations (above
knee to ankle), and minor amputations (forefoot to toe) were identified.
Total charges, including a breakdown of component charges, were com-
pared between groups.
Results: Lower extremity bypass procedures decreased 31% from
2000 to 2008 from 5294 to 3636. Hospital based endovascular inter-
ventions increased 113% during the same time points from 2698 to 5748.
Endovascular interventions performed at ambulatory centers showed a
121% increase in just 5 years from 2004 to 2008 (3014 vs 6670*).
Combined hospital and ambulatory based endovascular therapy exceeded
open bypass procedures by over threefold in 2008 (12,419 vs 3636) (Fig
1). Consistent with previous administrative database studies, major am-
putations decreased consistently each year, resulting in a 43% decrease
from 2000 to 2008 (2833 vs 1609), whereas minor amputations were
stable (1354 vs 1362). Total charges were highest for open bypass
($62,946  65,595), followed by hospital based endovascular proce-
dures ($57,995  58,008), and lowest for ambulatory endovascular
procedures ($32,719  16,574) (Table). Comparing specific charges for
hospital based endovascular vs open bypass procedures, higher charges
for medical/surgical supplies and radiology for endovascular procedures
was offset by savings in anesthesia, as well as shorter length of stay as
reflected in smaller charges for ICU/floor, medications, and laboratory
studies. Endovascular procedures at ambulatory centers had substantially
lower charges overall and in all of the major categories. Notably, among
over 20,000 discharges from ambulatory centers, there were two deaths,
and only 10 were transferred to inpatient care.
Conclusion: In Florida, rapid adoption of endovascular procedures,
particularly in ambulatory centers, has led to a decrease in open bypass
procedures and is associated with a continual decrease in major amputations.
For carefully selected patients, endovascular procedures performed in am-
bulatory centers are safe and offer significant cost savings. These data provide
the platform for a prospective, collaborative Florida Vascular Study Group
aimed at prospective quality improvement. * Projected 2008 ambulatory
data based on the first three quarters due to lack of Q4 data at the time of
submission
Table. Total and component charges by type of
procedure and setting
Open
bypass
Endovascular
(hospital)
Endovascular
(ambulatory)
Total charges $61,946 $57,995 $32,719
ICU/floor $ 7547 $ 4806 n/a
Medications/lab
studies
$14,466 $10,574 $ 1622
Medical/surgical
supply
$ 9559 $14,095 $11,151
Radiology
Studies/therapy
$ 3106 $ 8887 $ 7219
OR charges $13,922 $ 9854 $ 8905
Anesthesia charges $ 3487 $ 1007 $ 219
Recovery/observation $ 2025 $ 2183 $ 1176
Other $ 7834 $ 6589 $ 2427
